×
AbbVie Receivables 2010-2024 | ABBV
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
AbbVie receivables for the quarter ending December 31, 2024 were
$10.919B
, a
6.87% decline
year-over-year.
AbbVie receivables for 2024 were
$10.919B
, a
0% decline
from 2024.
AbbVie receivables for 2024 were
$10.919B
, a
2.12% decline
from 2023.
AbbVie receivables for 2023 were
$11.155B
, a
0% decline
from 2023.
View More
AbbVie Receivables 2010-2024 | ABBV
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
AbbVie receivables for 2024 were
$10.919B
, a
0% decline
from 2024.
AbbVie receivables for 2024 were
$10.919B
, a
2.12% decline
from 2023.
AbbVie receivables for 2023 were
$11.155B
, a
0% decline
from 2023.
Related Stocks
Company Name
Market
Cap
Eli Lilly (LLY)
$823.1B
Johnson & Johnson (JNJ)
$380.1B
Novo Nordisk (NVO)
$374.3B
Roche Holding AG (RHHBY)
$259.5B
Novartis AG (NVS)
$218.5B
Merck (MRK)
$216.5B
Pfizer (PFE)
$146.7B
Sanofi (SNY)
$136B
Bayer (BAYRY)
$22B
Innoviva (INVA)
$1.1B